Rohit Joshi, J. Goh, W. Joubert, Vineet Kwarta, M. Okera, S. Bishnoi, J. Lederer, F. Borriello, S. Gargosky
{"title":"SUPLEXA治疗细胞用于转移性实体瘤和血液恶性肿瘤患者的1期、首次人体、开放标签单药研究的临床更新","authors":"Rohit Joshi, J. Goh, W. Joubert, Vineet Kwarta, M. Okera, S. Bishnoi, J. Lederer, F. Borriello, S. Gargosky","doi":"10.1136/jitc-2022-sitc2022.0632","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"106 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies\",\"authors\":\"Rohit Joshi, J. Goh, W. Joubert, Vineet Kwarta, M. Okera, S. Bishnoi, J. Lederer, F. Borriello, S. Gargosky\",\"doi\":\"10.1136/jitc-2022-sitc2022.0632\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":398566,\"journal\":{\"name\":\"Regular and Young Investigator Award Abstracts\",\"volume\":\"106 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regular and Young Investigator Award Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jitc-2022-sitc2022.0632\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regular and Young Investigator Award Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jitc-2022-sitc2022.0632","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies